Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux for Anticoagulation in AF Cardioversion
NCT00911300Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2009
- Primary completion
- Sep 2011
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
A Phase 2 trial of fondaparinux in Atrial fibrillation (AFib), sponsored by GSK. Started Aug 2009; status: completed.
02
Drugs
fondaparinux
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00911300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00911300.